BICO

The world’s leading bioconvergence company.

Launch date

2016

Employees

Market cap

Enterprise valuation

$610m (Public information from Sep 2024)

Göteborgs Stad Västra Götaland County (HQ)

https://cellink.com/global/

https://twitter.com/cellink3d https://www.linkedin.com/company/cellink

Revenues, earnings & profits over time

USD	2019	2020	2021	2022	2023	2024	2025
Revenues	11.0m	21.4m	152m	271m	272m	294m	334m
% growth	100 %	94 %	611 %	78 %	-	8 %	14 %
EBITDA	<1m	(4.8m)	3.8m	39.0m	41.5m	23.5m	43.6m
% EBITDA margin	1 %	(22 %)	3 %	14 %	15 %	8 %	13 %
Profit	-	(7.5m)	(27.5m)	(101m)	(240m)	(11.6m)	(1.9m)
% profit margin	-	(35 %)	(18 %)	(37 %)	(88 %)	(4 %)	(1 %)
EV / revenue	35.8x	64.2x	13.8x	3.1x	2.2x	1.8x	1.7x
EV / EBITDA	4476.1x	-287.2x	545.2x	21.7x	14.6x	22.1x	12.8x

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Band of Angels GU Ventures AB	N/A	-
Oct 2015	Bosch Ventures	N/A	Seed
Oct 2016*	N/A	$8.9m	IPO
Jun 2017	Horizon 2020 FET (Future and Emerging Technologies)	€350k	Grant
Jun 2018*	Svenska Handelsbanken AP4 Carl Bennet Claes Dinkelspiel	€10.0m	Post IPO Equity
Jul 2018	European Innovation Council	€2.5m	Grant
Sep 2018	European Commission	€3.5m	Grant
Oct 2018	Franklin Templeton Investments	N/A	Post IPO Equity
Apr 2019	Eurostars SME programme	€480k	Grant
Mar 2020	Vinnova	$210k	Grant
Total Funding		$7.7m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by BICO Aug 2020

Phytosys (Visikol)

ACQUISITION by BICO May 2021

ACQUISITION by BICO Aug 2019

ACQUISITION by BICO Feb 2021

ACQUISITION by BICO May 2021

ACQUISITION by BICO Mar 2021

ACQUISITION by BICO Jun 2021

ACQUISITION by BICO May 2022